Amgen's Pipeline Shows Promise with MariTide and Expanding Drug Portfolio
Key Insights
Amgen is focusing on new drug launches, including the cancer (search) drug Lumakras, to replace revenue from older medications.
Tepezza, acquired by Amgen last year, is the first FDA-approved treatment for thyroid eye disease (search) (TED) and is expected to perform strongly, particularly in international markets.
MariTide, currently in phase two trials, shows potential in the weight loss market and may also have applications in treating diabetes (search), with analysts projecting significant revenue.
Amgen Inc. (AMGN) is strategically launching new drugs to rejuvenate its portfolio, replacing revenue from older, established medications. This initiative includes a focus on innovative treatments and expansion into high-growth therapeutic areas.
Strategic Drug Launches
Among the new launches is Lumakras, a cancer (search) drug with renewed sales expectations as the COVID-19 pandemic wanes. The company anticipates increased adoption and market penetration for this therapy.
Tepezza Acquisition and Thyroid Eye Disease
Last year's acquisition of Tepezza marked a significant addition to Amgen's portfolio. Tepezza is the first and only FDA-approved treatment for thyroid eye disease (search) (TED). The drug is expected to perform strongly, especially in foreign markets, addressing a critical unmet need in ophthalmology.
MariTide and the Weight Loss Market
Amgen is also making strides in the rapidly expanding weight loss market with MariTide, currently in phase two clinical trials. Data indicates that patients maintained weight loss for up to 150 days post-treatment. MariTide may also hold promise for treating diabetes (search). Analysts project potential revenues of $2.1 billion by 2030, highlighting its blockbuster potential.
Robust Pipeline
Beyond MariTide, Amgen boasts a rich pipeline with over 30 phase 3 programs, signaling a strong commitment to future growth and innovation across various therapeutic areas.